Board Meetings for BETA
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| BETA | Beta Drugs Limited | 14 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 | |
| BETA | Beta Drugs Limited | 14 May 2026 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 14-May-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2026 . | |
| BETA | Beta Drugs Limited | 14 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 | |
| BETA | Beta Drugs Limited | 14 Feb 2026 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 14-Feb-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2025 . | |
| BETA | Beta Drugs Limited | 09 Jan 2026 | Other business matters | To consider other business matters (a) acquisition of equity shares of a target company from certain shareholders of the target company; (b) issue certain equity shares to the shareholders of the target company on a preferential basis through the private placement route, as consideration other than cash in lieu of the acquired shares and(c) to consider and approve the Employee Stock Option Plan (ESOP). | |
| BETA | Beta Drugs Limited | 09 Jan 2026 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 09-Jan-2026 to consider and approve ESOP/Other business. | |
| BETA | Beta Drugs Limited | 06 Nov 2025 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2025 . | |
| BETA | Beta Drugs Limited | 06 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 | |
| BETA | Beta Drugs Limited | 15 May 2025 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 15-May-2025 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2025 . | |
| BETA | Beta Drugs Limited | 15 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 | |
| BETA | Beta Drugs Limited | 27 Mar 2025 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 27-Mar-2025 to consider Other business. | |
| BETA | Beta Drugs Limited | 27 Mar 2025 | Other business matters | To consider other business matters- To consider and approve the allotment of 4,80,693 fully paid-up equity shares of the Company of face value of INR 10 each, under Bonus Issue. | |
| BETA | Beta Drugs Limited | 05 Feb 2025 | Bonus/Other business matters | To consider bonus and other business matters including Migration of listing / trading of equity shares of the company from Emerge platform of National Stock Exchange of India Limited (NSE) to main board of National Stock Exchange of India Limited as well as on main board of BSE Ltd. | |
| BETA | Beta Drugs Limited | 05 Feb 2025 | Board Meeting Intimation | BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2025 to consider and approve Bonus/Other business. | |
| BETA | Beta Drugs Limited | 27 Nov 2024 | Other business matters | To consider other business matters 1. To consider & approve the allotment of 100 fully paid-up equity shares of the Company of face value of Rs. 10 each, at a price of Rs 1,653.40 per Equity Share including a premium of Rs. 1,643.40 per Equity Share and 7,07,651 fully paid up unsecured compulsory convertible debentures of the Company ( CCDs ) of face value of Rs. 1,653.40 each under Preferential Issue, pursuant to approval obtained from shareholders in Extra Ordinary General Meeting held on 12th November, 2024.2. To consider, approve & adopt the restated Article of Association of the company, subject to the approval of shareholders of the company in their meeting. |
Showing page 1 of 4 (55 total items)